Apollo Endosurgery, Inc.
Veteran Executive Brings 30 Years of Financial and Operational Leadership Experience
AUSTIN, TX / ACCESSWIRE / July 16, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Jeffrey G. Black as Chief Financial Officer. Mr. Black has served as Chief Financial Officer for a variety of publicly-traded companies in the medical device, diagnostics, life sciences, technology and industrial biotech industries.
"Jeff is a collaborative leader who builds and leads strong teams and has highly relevant experience for a company at our stage of growth," said Chas McKhann, president and CEO of Apollo Endosurgery. "His experience as a financial executive for seven publicly traded companies, the key relationships he has established on Wall Street, and his direct involvement in over $1 billion of strategic, equity and debt transactions will serve Apollo well as we advance our mission to bring innovative solutions to GI patients around the globe."
Mr. Black brings 30 years of experience to Apollo Endosurgery. Most recently, he served as Chief Financial Officer at Alphatec Holdings, Inc. (ATEC), a medical technology company providing spinal fusion solutions. He played a key role in the successful turnaround of the company, securing nearly $500 million in financing to support accelerated growth, transform the balance sheet, and execute strategic acquisitions. Under his leadership, Alphatec grew from a market capitalization of $20 million to more than $1.5 billion. Prior to Alphatec, he worked as Chief Financial Officer for Applied Proteomics, Inc, where he built a finance team that transitioned the company from pre-commercial stage to launching a blood-based cancer diagnostic.
Mr. Black also served as CFO for AltheaDx, Inc. and Verenium Corporation (formerly Diversa Corporation) (VRNM). During his nine-year tenure at Verenium/Diversa, Mr. Black played a leadership role in scaling the organization and in executing more than $500 million in strategic financing, M&A, collaborative, and licensing transactions, culminating in the successful sale of the company to BASF in 2013.
"I'm pleased to join the high-caliber Apollo leadership team," said Black. "I believe Apollo is very well-positioned to transform the market with a truly differentiated suite of products and technologies. I'm excited to be a part of the company's next phase of growth, with a focus on changing patient lives and building value for Apollo's shareholders."
Stefanie Cavanaugh, who has served Apollo as CFO since March 2015, will remain with the Company. McKhann added, "We are extremely pleased that Stefanie will remain with Apollo as we scale the finance function and our organization to achieve our growth aspirations. Stefanie is a valued member of the Apollo leadership team and has deep knowledge of Apollo's business." Mr. Black will assume the position and responsibilities of CFO immediately following Apollo's filing of the Quarterly Report for the quarter ending June 30, 2021.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on the development of next-generation, less invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, management of gastrointestinal complications and the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo's common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information on Apollo Endosurgery visit www.apolloendo.com.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. In addition, there is uncertainty about the continued spread of the COVID-19 virus and the impact it may have on the Company's operations, the demand for the Company's products, the Company's liquidity position, global supply chains and economic activity in general. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, outcomes of clinical studies related to our products, development of competitive products or procedures, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory authorities, unfavorable media coverage related to our products or related procedures, coverage and reimbursement decisions by private or government payors, Apollo's ability to support the adoption of its products and broaden its product portfolio; the potential size of Apollo's addressable markets; the execution of our gross margin improvement projects; the availability of cash for Apollo's future operations as well as other factors detailed in Apollo's periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2020 and its Form 10-Q for the period ending March 31, 2021. Copies of reports filed with the SEC are posted on Apollo's website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
CONTACT:
Investors:
Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com
Media:
Health + Commerce
Laurel Hood, 218-341-7270
Laurel@healthandcommerce.com
SOURCE: Apollo Endosurgery, Inc.
View source version on accesswire.com:
https://www.accesswire.com/655768/Apollo-Endosurgery-Appoints-Jeffrey-G-Black-as-Chief-Financial-Officer
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI and Calidus Sign MOU To Collaborate on Co-Production of MQ-9B and Gambit Collaborative Combat Aircraft20.1.2026 18:00:00 CET | Press release
ABU DHABI, UAE / ACCESS Newswire / January 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in unmanned aircraft systems, and Calidus Aerospace, one of the leading defense and manufacturing companies, have signed a Memorandum of Understanding (MOU) to collaborate on the prospective co-production of MQ-9B Remotely Piloted Aircraft and Gambit Collaborative Combat Aircraft (CCA) in the UAE, as well as command and control and battle management systems. The agreement was signed by GA-ASI President David R. Alexander and Dr. Khalifa Murad Alblooshi, Managing Director and CEO of Calidus Holding Group, on the sidelines of the UMEX and SimTEX 2026 taking place January 20-22, 2026. The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Calidus where all parties will look to collaborate on programs in the areas of airframe manufacturing, final assembly, test and checkout, as well as flight operational test and acceptance. "Working with pa
Vossen Capital Management Secures £200 Million in Pre-IPO Investment Commitments20.1.2026 15:20:00 CET | Press release
Vossen Capital Management Ltd ("Vossen Capital" or the "Company"), a specialist investment firm focused on fixed income and private market opportunities, announces that it has secured £200 million in committed capital for its Pre-IPO Investment Programme. LONDON, UK / ACCESS Newswire / January 20, 2026 / Highlights: £200 million committed to Pre-IPO allocations across technology, healthcare, and sustainable infrastructure sectors Expanded institutional partner network providing enhanced deal flow access Strong investor demand driven by track record of successful Pre-IPO placements Programme offers qualified investors early-stage exposure to growth companies ahead of public listings The capital commitments have been secured from a combination of institutional investors, family offices, and high-net-worth individuals seeking exposure to private market opportunities typically reserved for venture capital and institutional funds. Jack Vossen, Head of Private Equity at Vossen Capital, comme
Innodata Awarded Prime Contract Position on U.S. Missile Defense Agency's IDIQ SHIELD Program20.1.2026 14:30:00 CET | Press release
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract. The SHIELD program is designed to drive rapid innovation and deliver next-generation capabilities that strengthen the nation's multi-layered homeland defense architecture. As part of the broader Golden Dome strategy, this selection positions Innodata to compete for future task orders across research, development, engineering, prototyping, and operations of critical Missile Defense Agency systems that support U.S. national security objectives. The award was made as part of a list of companies eligible to compete under the program publicly announced by the U.S. Government on 15-Jan-26. "We are proud to support our nation's mission to defend the homeland," said Vinay Malkani, SVP Federal of Innodata. "This co
Karbon-X Secures up to $25 Million in Strategic Financing to Accelerate Growth and Expand Global Climate Solutions Platform20.1.2026 14:30:00 CET | Press release
CALGARY, AB / ACCESS Newswire / January 20, 2026 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate-solutions company operating across compliance and voluntary carbon markets, today announced that it has secured access to up to $25 million in discretionary financing, providing the Company with enhanced flexibility to scale its platform, deepen market participation, and capitalize on strategic growth opportunities as global carbon markets continue to mature. The financing supports the Company's ability to execute its growth strategy with discipline, while remaining responsive to evolving regulatory frameworks and market demand. "This financing enhances our ability to execute with focus and flexibility," said Chad Clovis, Chief Executive Officer of Karbon-X. "Access to capital allows us to scale areas of the business that are already performing, selectively invest in growth, and pursue opportunities aligned with our long-term value creation strategy." The financing is intende
Polaris Renewable Energy Declares Quarterly Dividend20.1.2026 13:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / January 20, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on February 27th to shareholders of record at the close of business on February 17th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom